Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

AIDS

Volumn 15, Issue 6, 2001, Pages 675-681

  Jones, Kevin ^a   Hoggard, Patrick G ^a   Sales, Sean D ^a   Khoo, Saye ^a   Davey, Ross ^b   Back, David J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Accumulation; Antiretroviral therapy; Multidrug resistance associated protein; P glycoprotein; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CARBON 14; COMPLEMENTARY DNA; DEOXYGLUCOSE; EPIRUBICIN; INDINAVIR; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; ROTENONE; SAQUINAVIR; TRITIUM; VINBLASTINE;

ACTIVE TRANSPORT; ARTICLE; CELL CULTURE; CELL LEVEL; CONTROLLED STUDY; DRUG PROTEIN BINDING; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOBLASTOID CELL; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NELFINAVIR; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; SAQUINAVIR;

EID: 0035853376     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200104130-00002     Document Type: Article

References (22)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients, a prospective cohort study. Swiss Cohort Study
3. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter
4. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters
5. Expression of a multidrug resistance gene in human cancers
6. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites
7. Barrier properties of testis microvessels
8. Multidrug resistance activity in human lymphocytes
9. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
10. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
11. Expression of multidrug resistance-associated protein (MRP) in brain microvessel endothelial cells
12. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells
13. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer
14. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line
15. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture
16. Human immunodeficiency virus I-induced expression of P-glycoprotein
17. Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection
18. Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients
19. P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients
20. Transmembrane P-glycoprotein (P-gp P-170) in HIV infection: Analysis of lymphocyte surface expression and drug-unrelated function
21. May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors
22. 1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro